CDK4/6i in HR+HER2- breast cancer
e-ESO Podcasts - Un pódcast de ESO - European School of Oncology
Categorías:
Expert: Nadia Harneck, Breast Center, LMU University Hospital, Munich, Germany Questions: 1.The best hormonal partner: evidence on fulvestrant, letrozole or anastrozole. 2.Possibility to use CDK4/6i+AI in mBC in patients progressing during or after completion of adjuvant AI treatment. 3.Ways of overcoming haematologic toxicities (neutropenia, leucopenia). 4.Any evidence on choosing between three drugs of this class currently available (palbociclib, ribociclib, abemaciclib). 5.Possible biomarkers of response and effectiveness.
